Top

Trials

Published in:

Open Access 01-12-2022 | Study protocol

Efficacy and safety of Qushi Huayu granule for hyperlipidemia: study protocol for a randomized, double-blind, placebo-controlled trial

Authors: Yuanlong Sun, Na Hu, Gaofeng Chen, Yanjie Wang, Yiyang Hu, Maojun Ge, Yu Zhao

Published in: Trials | Issue 1/2022

Abstract

Background

Hyperlipidemia has become a common chronic disease worldwide in recent years. Studies have shown that hyperlipidemia patients, especially those with a high level of serum low-density lipoprotein cholesterol (LDL-C), have a significantly higher prevalence of atherosclerosis, leading to coronary heart disease. Previous basic experiments and clinical studies have shown that Qushi Huayu granules (QSHY) reduce blood lipids in patients with non-alcoholic fatty liver disease (NAFLD) accompanied by hyperlipidemia. However, the clinical efficacy of QSHY in patients with hyperlipidemia is still lacking. This study aims to investigate the effect and safety of QSHY for hyperlipidemia.

Methods

This is a randomized, double-blind, placebo-controlled trial. A total of 210 participants will be enrolled and randomized into the QSHY or placebo granules groups in equal proportions, who will receive treatment for 24 weeks. The primary outcome will be the change in LDL-C from baseline to week 12. Secondary outcomes will be changes in other serum lipids markers, life quality measuring health surveys, and traditional Chinese medicine (TCM) pattern scale. All related tests will be measured at baseline, week 12, and week 24 after enrollment. Adverse events and the safety of intervention will be monitored and evaluated.

Discussion

We designed a clinical trial of hyperlipidemia management with QSHY, a TCM prescription. The results of this trial will present the efficacy and safety of QSHY in patients with hyperlipidemia.

Trial registration

Chinese Clinical Trial Registry ChiCTR2000034125. Registered on June 25, 2019

Karr S. Epidemiology and management of hyperlipidemia. Am J Manag Care. 2017;23(9 Suppl):S139–S48.PubMed

Benjamin E, Muntner P, Alonso A, Bittencourt M, Callaway C, Carson A, et al. Heart Disease and Stroke Statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–e528.CrossRefPubMed

Li Y, Chao T, Liu P, Ueng K, Yeh H. Lipid lowering therapy for acute coronary syndrome and coronary artery disease: highlights of the 2017 Taiwan Lipid Guidelines for High Risk Patients. Acta Cardiologica Sinica. 2018;34(5):371–8. https://doi.org/10.6515/ACS.201809_34(5).20180629A.CrossRefPubMedPubMedCentral

Cybulsky M, Cook S, Kontsevaya A, Vasiljev M, Leon D. Pharmacological treatment of hypertension and hyperlipidemia in Izhevsk, Russia. BMC Cardiovasc Disord. 2016;16(1):122. https://doi.org/10.1186/s12872-016-0300-9.CrossRefPubMedPubMedCentral

Hegele RA, Ginsberg HN, Chapman MJ, Nordestgaard BG, Kuivenhoven JA, Averna M, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014;2(8):655–66. https://doi.org/10.1016/S2213-8587(13)70191-8.CrossRefPubMed

Birnbaum RA, Horton BH, Gidding S, Brenman LM, Avins AL. Closing the gap: identification and management of familial hypercholesterolemia in an integrated healthcare delivery system. J Clin Lipidol. 2021;22(2):347–57. https://doi.org/10.1016/j.jacl.2021.01.008.CrossRef

Moran A, Gu D, Zhao D, Coxson P, Wang Y, Chen C, et al. Future cardiovascular disease in china: Markov model and risk factor scenario projections from the coronary heart disease policy model-china. Circ Cardiovasc Q Outcome. 2010;3(3):243–52. https://doi.org/10.1161/CIRCOUTCOMES.109.910711.CrossRef

Schmitz G, Orsó E. Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects. Clin Res Cardiol Suppl. 2015;10(S1):21–5. https://doi.org/10.1007/s11789-015-0074-0.CrossRefPubMedPubMedCentral

Arnesen K, Phung A, Randsborg K, Mork I, Thorvall M, Langslet G, et al. Risk of recurrent coronary events in patients with familial hypercholesterolemia; a 10-years prospective study. Front Pharmacol. 2020;11:560958. https://doi.org/10.3389/fphar.2020.560958.CrossRefPubMed

10.

Lian X, Zhang Y, Li X, Jing L, Cairang Z, Gou J. Exploration on the relationship between the elderly osteoporosis and cardiovascular disease risk factors. Eur Rev Med Pharmacol Sci. 2017;21(19):4386–90.PubMed

11.

Chang HJ, Lin KR, Chang JL, Lin MT. Risk factors for chronic kidney disease in older adults with hyperlipidemia and/or cardiovascular diseases in Taipei City, Taiwan: a community-based cross-sectional analysis. Int J Environ Res Public Health. 17(23):8763.

12.

Speer T, Ridker PM, Eckardstein AV, Schunk SJ, Fliser D. Lipoproteins in chronic kidney disease: from bench to bedside. Eur Heart J. 2021;42(22):2170–85. https://doi.org/10.1093/eurheartj/ehaa1050.CrossRefPubMed

13.

Carr R, Rejowski B, Cote G, Pitt H, Zyromski N. Systematic review of hypertriglyceridemia-induced acute pancreatitis: a more virulent etiology? Pancreatology. 2016;16(4):469–76.CrossRefPubMed

14.

Kopin L, Lowenstein C. Dyslipidemia. Ann Int Med. 2017;167(11):ITC81–96. https://doi.org/10.7326/AITC201712050.CrossRefPubMed

15.

Laufs U, Parhofer K, Ginsberg H, Hegele R. Clinical review on triglycerides. Eur Heart J. 2020;41(1):99–109c.CrossRefPubMed

16.

Volgman A, Palaniappan L, Aggarwal N, Gupta M, Khandelwal A, Krishnan A, et al. Atherosclerotic cardiovascular disease in South Asians in the United States: epidemiology, risk factors, and treatments: a scientific statement from the American Heart Association. Circulation. 2018;138(1):e1–e34. https://doi.org/10.1161/CIR.0000000000000580.CrossRefPubMed

17.

Catapano A, Graham I, De Backer G, Wiklund O, Chapman M, Drexel H, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;253:281–344. https://doi.org/10.1016/j.atherosclerosis.2016.08.018.CrossRefPubMed

18.

Lavecchia A, Cerchia C. Recent advances in developing PCSK9 inhibitors for lipid-lowering therapy. Future Med Chem. 2019;11(5):423–41. https://doi.org/10.4155/fmc-2018-0294.CrossRefPubMed

19.

Suresh A, Narayan R, Nayak U. Recent advances in the development of asenapine formulations. Expert Opin Drug Deliv. 2020;17(10):1377–93. https://doi.org/10.1080/17425247.2020.1792439.CrossRefPubMed

20.

Tomlinson B, Chan P, Zhang Y, Liu Z, Lam C. Pharmacokinetics of current and emerging treatments for hypercholesterolemia. Expert Opin Drug Metab Toxicol. 2020;16(5):371–85. https://doi.org/10.1080/17425255.2020.1749261.CrossRefPubMed

21.

Walsh J, Pignone M. Drug treatment of hyperlipidemia in women. JAMA. 2004;291(18):2243–52. https://doi.org/10.1001/jama.291.18.2243.CrossRefPubMed

22.

McEvoy J, Blumenthal R, Blaha M. Statin therapy for hyperlipidemia. JAMA. 2013;310(11):1184–5. https://doi.org/10.1001/jama.2013.276734.CrossRefPubMed

23.

Sakamoto K, Kimura J. Mechanism of statin-induced rhabdomyolysis. J Pharmacol Sci. 2013;123(4):289–94. https://doi.org/10.1254/jphs.13R06CP.CrossRefPubMed

24.

Bellosta S, Corsini A. Statin drug interactions and related adverse reactions: an update. Expert Opin Drug Saf. 2018;17(1):25–37. https://doi.org/10.1080/14740338.2018.1394455.CrossRefPubMed

25.

Mohamed M, Salameh O, Saeed A. Statin-induced rhabdomyolysis, acute kidney injury, and hepatitis leading to death. Am J Case Rep. 2019;20:709–12. https://doi.org/10.12659/AJCR.914707.CrossRefPubMedPubMedCentral

26.

Sharma P, Timilsina B, Adhikari J, Parajuli P, Dhital R, Tachamo N. Statin-induced necrotizing autoimmune myopathy: an extremely rare adverse effect from statin use. J Commun Hosp Int Med Perspect. 2019;9(6):503–6. https://doi.org/10.1080/20009666.2019.1702272.CrossRef

27.

Kim Y, Han Y, Choi E, You N, Lee J, You H, et al. Statin use increased new-onset diabetes in hypercholesterolemic individuals: data from the Korean National Health Insurance Service-National Health Screening Cohort database (NHIS-HEALS). Prim Care Diabetes. 2020;14(3):246–53. https://doi.org/10.1016/j.pcd.2019.08.005.CrossRefPubMed

28.

Zhang L, Zhang J, Feng R, Jin X, Yang F, Ji Z, et al. Efficacy and safety of berberine alone or combined with statins for the treatment of hyperlipidemia: a systematic review and meta-analysis of randomized controlled clinical trials. Am J Chin Med. 2019;47(4):751–67. https://doi.org/10.1142/S0192415X19500393.CrossRefPubMed

29.

Weidong Q, Jiwei W, Haiting L. Research progress on treatment of hyperlipidemia from phlegm and blood stasis. J Sichuan Tradit Chin Med. 2014;32(12):185–7.

30.

Zhao S, Liu L, Cheng Y, Shishehbor M, Liu M, Peng D, et al. Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation. 2004;110(8):915–20. https://doi.org/10.1161/01.CIR.0000139985.81163.CE.CrossRefPubMed

31.

Nan H. Effect of Zhibituo tablet on hyperlipidemia. Guide China Med. 2012;10(12):657–8.

32.

Chenxi L, Ruixia L. Effect of Zhi Bi Tai Capsule on type 2 diabetes mellitus with hyperlipidemia. World Latest Med Inform. 2019;19(20):168–9.

33.

Zongsheng Q. Clinical effect of Qushi Huayu decoction on nonalcoholic fatty liver disease. Chin J Clin Ration Drug Use. 2015;8(15):135–6.

34.

Li H, Feng Q, Zhu D, Ying H, Li D, Fu Q. Clinical observation of Qushi Huayu decoction in the treatment of nonalcoholic steatohepatitis with phlegm and blood stasis. Chin Arch Tradit Chin Med. 2013;31(08):1764–7.

35.

Gou XJ, Gao S, Chen L, Feng Q, Hu YY. A metabolomic study on the intervention of traditional Chinese medicine Qushi Huayu decoction on rat model of fatty liver induced by high-fat diet. Biomed Res Int. 2019;2019:5920485–14. https://doi.org/10.1155/2019/5920485.CrossRefPubMedPubMedCentral

36.

Gou XJ, Feng Q, Fan LL, Zhu J, Hu YY. Serum and liver tissue metabonomic study on fatty liver in rats induced by high-fat diet and intervention effects of traditional Chinese medicine Qushi Huayu decoction. Evid Based Complement Alternat Med. 2017;2017:6242697–12. https://doi.org/10.1155/2017/6242697.CrossRefPubMedPubMedCentral

37.

Feng Q, Gou XJ, Meng SX, Huang C, Zhang YQ, Tang YJ, et al. Qushi Huayu decoction inhibits hepatic lipid accumulation by activating AMP-activated protein kinase in vivo and in vitro. Evid Based Complement Alternat Med. 2013;2013:184358–14. https://doi.org/10.1155/2013/184358.CrossRefPubMedPubMedCentral

38.

Feng Q, Liu W, Baker S, Li H, Chen C, Liu Q, et al. Multi-targeting therapeutic mechanisms of the Chinese herbal medicine QHD in the treatment of non-alcoholic fatty liver disease. Oncotarget. 2017;8(17):27820–38. https://doi.org/10.18632/oncotarget.15482.CrossRefPubMedPubMedCentral

39.

Junren Z, Runlin G, Guangping Z, Guoping L, Dong Z, Jianjun L. Guidelines for the prevention and treatment of dyslipidemia in Chinese adults (revised in 2016). Chin Circ J. 2016;31(10):937–53.

40.

Xuezhi Z. Diagnosis and treatment standard of dyslipidemia in traditional Chinese medicine (Draft). Chin J Tradit Chin Med. 2008;23(8):716–9.

41.

Keech A, Simes RJ, Barter P, Best J, Fassett R. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–61. https://doi.org/10.1016/S0140-6736(05)67667-2.CrossRefPubMed

42.

Peng J, Hu Y, Feng Q, Cheng Y, Xu L, Chen S, et al. Effect of Jianpi Huoxue decoction-containing serum on tumor necrosis factor-alpha secretion and gene expression of endotoxin receptors in RAW264.7 cells induced by lipopolysaccharide. Chin J Integr Med. 2009;15(3):198–203. https://doi.org/10.1007/s11655-009-9001-x.CrossRefPubMed

43.

Yumei C. Qushi Huayu decoction combined with western medicine in the treatment of nonalcoholic fatty liver. J Pract Tradit Chin Intern Med. 2015;29(04):110–1.

44.

Mach F, Baigent C, Catapano A, Koskinas K, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. https://doi.org/10.1093/eurheartj/ehz455.CrossRefPubMed

Title: Efficacy and safety of Qushi Huayu granule for hyperlipidemia: study protocol for a randomized, double-blind, placebo-controlled trial
Authors: Yuanlong Sun
Na Hu
Gaofeng Chen
Yanjie Wang
Yiyang Hu
Maojun Ge
Yu Zhao
Publication date: 01-12-2022
Publisher: BioMed Central
Published in: Trials / Issue 1/2022
Electronic ISSN: 1745-6215
DOI: https://doi.org/10.1186/s13063-022-06031-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Efficacy and safety of Qushi Huayu granule for hyperlipidemia: study protocol for a randomized, double-blind, placebo-controlled trial

Abstract

Background

Methods

Discussion

Trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Discussion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2022

Efficacy and safety of EXOWALK® on electromechanical-assisted gait training: study protocol for randomized controlled trial

Does serum progesterone level impact the ongoing pregnancy rate in frozen embryo transfer under artificial preparation with vaginal progesterone? Study protocol for a randomized controlled trial

Effect of vaginal antiseptic prior to caesarean section on the rate of post-caesarean complications: a blinded randomised controlled trial

The effects of acupuncture on psychological symptoms in patients with insomnia: study protocol for a randomized controlled trial

Nurse-led self-management support after organ transplantation—protocol of a multicentre, stepped-wedge randomized controlled trial

Pediatric Tuina in children with autism spectrum disorder: a study protocol for a randomized controlled trial